With the pharmaceutical sector preparing for the largest “patent cliff” in 15 years, licensing deals are a vital part of the strategy for Big Pharma to maintain and grow their portfolios. Speaking recently with Lexpert, Paul Armitage, head of the Vancouver technology industry group at Gowling WLG, discussed the central role licensing is playing in 2025 and beyond and other key trends in current license deals in the life sciences.

“Licensing has always been one of the core business strategies for biotech and pharma companies,” says Armitage. “Some years will have more deals, and some will have less. The way 2025 is unfolding, it looks like there will be a decent rate of major licensing deals.”

To read the full article, click the link below (subscription may be required):

About Gowling WLG’s Technology Industry Group

From seed to exit, Gowling WLG's Technology Group helps entrepreneurs, startups and high-growth companies anticipate legal challenges, seize new opportunities and thrive in competitive markets. Our team advises a wide range of technology clients—from fintech, health tech and SaaS innovators to cleantech, agritech and AI leaders—as well as the investors who fund them. Learn more.